Quick Answer
SUTRO BIOPHARMA, INC. reported Cash And Cash Equivalents At Carrying Value of $58.13 million for the year ending 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -69.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $25.41 million | Q1 2018: $6.63 million | Q2 2018: $25.42 million | Q3 2018: $41.35 million | Q1 2019: $26.62 million | Q2 2019: $19.39 million | Q3 2019: $11.95 million | Q1 2020: $43.57 million | Q2 2020: $65.35 million | Q3 2020: $64.37 million | Q1 2021: $55.82 million | Q2 2021: $56.39 million | Q3 2021: $30.71 million | Q1 2022: $28.90 million | Q2 2022: $79.12 million | Q3 2022: $96.78 million | Q1 2023: $62.47 million | Q2 2023: $235.10 million | Q3 2023: $81.83 million | Q1 2024: $65.22 million | Q2 2024: $90.79 million | Q3 2024: $174.58 million | Q1 2025: $106.23 million | Q2 2025: $64.03 million | Q3 2025: $65.93 million.
- Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 401.4%.
- Historical annual values: Fiscal year 2025: $58.13 million | Fiscal year 2024: $190.30 million | Fiscal year 2023: $69.27 million | Fiscal year 2022: $47.25 million | Fiscal year 2021: $30.41 million | Fiscal year 2020: $206.15 million | Fiscal year 2019: $4.96 million | Fiscal year 2018: $125.30 million | Fiscal year 2017: $22.02 million | Fiscal year 2016: $11.59 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: